Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates mixed signals: strong market share growth and product launches are positive, but macroeconomic factors and reduced consumer demand are concerning. The Q&A reveals uncertainties, such as the impact of promotions and consumer sentiment. Despite positive long-term targets and a strong product launch, the immediate outlook is tempered by economic challenges and cautious guidance adjustments. Without a clear market cap, it's challenging to predict a strong movement, hence a neutral rating is appropriate.
Key Financial Performance
Global net revenue for Q2 2025 $69.4 million, a 4% increase over Q2 2024. Sales growth was driven by the successful launch of Evolysse and international revenue growth.
Net revenue breakdown for Q2 2025 $59.7 million from toxin revenue and $9.7 million from HA gels revenue.
Reported gross margin for Q2 2025 65.3%, with an adjusted gross margin of 66.5%. Margins were impacted by a higher mix of international sales and an introductory pricing offer for Evolysse.
GAAP operating expenses for Q2 2025 $55.5 million, down from $61.8 million in Q1 2025.
Non-GAAP operating expenses for Q2 2025 $54 million compared to $52.9 million in Q1 2025.
Non-GAAP operating loss for Q2 2025 $7.9 million compared to non-GAAP operating income of $1.1 million in Q2 2024.
Cash at the end of Q2 2025 $61.7 million, down from $67.9 million at the end of Q1 2025. The decrease was primarily driven by pulling forward inventory purchases ahead of increased tariffs.
Evolysse revenue for Q2 2025 $9.7 million, marking the strongest first-quarter filler launch in over a decade.
Evolus Rewards redemptions for Q2 2025 Over 224,000, with 65% coming from repeat patients, highlighting strong brand loyalty and consumer satisfaction.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Evolysse launch: Evolysse generated $9.7 million in revenue in its first quarter, marking the strongest first-quarter filler launch in over a decade. Over 4,000 healthcare providers were trained, and over 1,000 accounts ordered the product.
Jeuveau performance: Jeuveau experienced its first-ever year-over-year decrease but maintained a 14% market share, up from 13% in 2024. It outperformed the U.S. market with unit growth in the first half of the year.
International expansion: Evolus is now active in 9 international markets, covering over 70% of its international total addressable market. The company launched Nuceiva in France and aims to achieve $100 million in international revenue by 2028.
Cost optimization: Evolus implemented $25 million in operating expense cost savings, focusing on non-customer-facing areas while maintaining investments in customer-facing activities.
Revenue guidance: 2025 revenue guidance was reset to $295 million to $305 million, reflecting 11% to 15% growth over 2024.
Strategic shifts in operations: Evolus realigned its operating model to preserve profitability and sustain growth, including leveraging automation and AI to enhance productivity.
Focus on long-term growth: The company reaffirmed its goal of achieving $700 million in revenue and 20% non-GAAP operating income margins by 2028.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Environment: The company faced one of the most challenging market environments in recent years, with Jeuveau experiencing its first-ever year-over-year decrease due to a sharp reduction in consumer sentiment and broad softness in the U.S. aesthetic toxin market.
Procedural Volumes: Procedural volumes across the U.S. toxin category decelerated for three consecutive quarters, impacting Jeuveau demand for the first time.
Consumer Spending: Consumer discretionary spending remains under pressure, affecting demand in the aesthetic market.
Revenue Guidance: The company had to revise its 2025 revenue outlook downward to reflect current U.S. market trends.
Operating Expenses: Strategic reductions in operating expenses were implemented, including $25 million in cost savings, but these actions could pose risks to operational efficiency and employee morale.
Tariffs: Evolysse products sourced from France will be subject to a 15% tariff starting August 7, which could impact costs and margins.
Inventory Management: The company had to pull forward inventory purchases to mitigate tariff exposure, which impacted cash reserves.
International Revenue: While international markets are growing, the near-term revenue contribution from new launches like Nuceiva in France is expected to be modest.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Market Recovery and Patient Volume: Survey results indicate a meaningful rebound in patient volume in the second half of 2025, with a majority of practices expecting growth of more than 10%.
2025 Revenue Guidance: Revenue expectations for 2025 have been reset to a range of $295 million to $305 million, representing 11% to 15% growth over 2024.
Long-term Revenue Target: The company reaffirms its long-term revenue target of $700 million by 2028.
Evolysse Revenue Contribution: Evolysse is expected to contribute 10% to 12% of total revenue for the full year 2025.
Non-GAAP Operating Expense Guidance: Non-GAAP operating expenses for 2025 are projected to be between $208 million and $213 million, reflecting $25 million in cost savings.
Profitability Goals: The company aims to achieve positive non-GAAP operating income in Q4 2025 and annual profitability starting in 2026.
International Revenue Growth: The company is on track to achieve $100 million in international revenue by 2028.
Evolysse Market Penetration: Evolysse has shown strong early adoption, with full-year revenue contribution raised to 10% to 12% of total revenue for 2025.
Pipeline Developments: The Sculpt product is targeting approval in the second half of 2026, and a lips product is expected to gain approval in 2027.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:To what extent are you seeing reduced demand related to consumer sentiment versus increased competitor presence?
A:Management believes that procedural demand declined high single digits in the first half of the year, but they do not attribute this to competitive dynamics. Instead, they see it as a broader market demand issue. They noted that demand fell significantly in the last two weeks of the quarter due to macroeconomic factors and reduced purchasing by top-tier accounts.
Q:Can you quantify the amount of inventory buy-in there was for the $9.7 million recorded for Evolysse?
A:Management stated that the initial portion of revenue had a stocking element as well as pull-through. They estimated it as a relatively even mix of the two but noted that this is not precise math.
Q:What explains the meaningful improvement in July after no follow-through in the last two weeks of June?
A:Management explained that the improvement in July was incremental and not a full rebound. They attributed the June slowdown to accounts not placing large orders as they historically did, due to macroeconomic challenges and reduced consumer demand.
Q:Did Hugel have any impact on the market with their free product sampling?
A:Management acknowledged that Hugel samples heavily but stated that its impact on the overall toxin market in the second quarter was very small and not a key driver.
Q:Can you clarify the toxin demand trends and whether the impact was more pronounced on the low end of the market?
A:Management noted that third-party data showed a high single-digit decline in procedural volume in the first half of the year. They observed that the impact was more pronounced among consumers earning $150,000 or less annually, who are feeling the effects of increased prices and economic uncertainty.
Q:How do you expect to reach about $140 million Jeuveau revenue in H2 and market stimulation or promotional activity in Q4?
A:Management adjusted their promotional strategy for Jeuveau, including subsidizing consumer costs through the Evolus Rewards program and collaborating with a beauty magazine for a gift-with-purchase campaign. They believe these activities will help drive pull-through and support growth.
Q:What would drive the rebound in consumer demand, and how should we think about the sequence of the second half of the year?
A:Management expects an incremental improvement in the second half due to a more depressed base in the first half and some positive consumer sentiment surveys. They anticipate faster growth in the back half, with the fourth quarter being stronger than the third.
Q:What is driving the different consumer sentiment at this time compared to prior recessions?
A:Management believes that consumers earning $150,000 or less are feeling the effects of increased prices and economic uncertainty, which is impacting their spending on treatments. They noted that higher-income consumers are weathering the situation better.
Q:Have there been any changes to price levels due to tariffs or to address depressed consumer sentiment?
A:Management stated that they have not seen price increases related to tariffs for neurotoxins, as drugs are not impacted by tariffs. They also noted that there are always competitive dynamics, but nothing significant has changed in terms of pricing.
Q:How should we reconcile the reduction in guidance with the commentary about a recovery in July?
A:Management clarified that the reduction in guidance reflects the unexpected slowdown in the last two weeks of the second quarter. While they saw an incremental improvement in July, they do not expect a full rebound in the third quarter and have adjusted their guidance accordingly.
Q:How should we think about the trajectory of Evolysse given the strong launch?
A:Management expects the third quarter to be softer in terms of demand than the fourth quarter. They believe the strong launch metrics and positive feedback will support growth, but they caution against setting overly high expectations for the third quarter.
Q:How is the go-to-market strategy for Evolysse being received, and are there any plans for bundling opportunities with Jeuveau?
A:Management reported strong reception to the Evolysse launch, with high participation in training programs and positive media coverage. They believe Jeuveau is well-positioned in the market and are leaning into consumer marketing to support growth. They did not specifically mention bundling opportunities.
Q:What are the levers to achieve the 2028 targets given the deceleration in the toxin market?
A:Management stated that their internal forecast remains at or above the $700 million target for 2028. They have adjusted their models to reflect the revised guidance but believe the fundamentals of their business and growth drivers remain intact.
Q:Review of Unclear Management Responses
A:Management avoided providing precise quantification for the inventory buy-in for Evolysse, stating that it was a relatively even mix of stocking and pull-through but not providing exact numbers. They also did not provide specific guidance for the third quarter trajectory of Evolysse or detailed levers for achieving the 2028 targets, instead offering general statements about their confidence in the business fundamentals.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BOTOX
Chief Medical
Evolus Rewards
Instructions
LLC Research
Medical Officer
Moatazedi President
Nareg Sagherian
Officer Head
Research Division
action commitment
approval
consumer spending
cost
day
demand
duration
effect
endpoint
facing
feedback
head
investigator
launch Evolysse
majority
onset
order volume
outlook
position market
provider
quarter
reduction
softness
start
study
survey
volume toxin
website
EOLS Transcript
Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call summary and Q&A reveal several positive indicators, such as strong international growth, effective bundling strategies, and stable market sentiment despite competition. The company maintains healthy margins and anticipates FDA approval for new products. While some responses lacked specificity, the overall sentiment is optimistic, with guidance aligning with consensus estimates and expected growth in key markets. These factors suggest a likely positive stock price movement over the next two weeks.
Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript
Positive3-4
Evolus reported strong financial performance with a 25% YoY revenue increase and improved gross margins. Net income turned positive, reflecting effective cost management. Despite no mention of dividends or buybacks, the solid growth figures and profitability improvements are positive indicators. The absence of negative Q&A feedback further supports a positive sentiment. However, lack of market cap data limits precise prediction.
Evolus, Inc. (EOLS) Q3 2025 Earnings Call Transcript
Positive11-8
The earnings call and Q&A reflect a positive outlook, with strong product adoption, strategic cost optimization, and promising guidance for Q4. Despite some headwinds, the company anticipates a strong Q4, supported by effective marketing strategies and expected seasonal demand. The positive sentiment is further bolstered by the focus on expanding training for Evolysse, strategic bundling with Jeuveau, and the potential for long-term revenue growth. However, the lack of specific guidance on tariffs and sales splits introduces some uncertainty, warranting a cautious but optimistic rating.
Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript
Unknown8-5
The earnings call summary indicates mixed signals: strong market share growth and product launches are positive, but macroeconomic factors and reduced consumer demand are concerning. The Q&A reveals uncertainties, such as the impact of promotions and consumer sentiment. Despite positive long-term targets and a strong product launch, the immediate outlook is tempered by economic challenges and cautious guidance adjustments. Without a clear market cap, it's challenging to predict a strong movement, hence a neutral rating is appropriate.
EOLS Slides
EOLS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
